Earnings Results
Citius Pharma (NASDAQ:CTXR) reported quarterly earnings results on August 14, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.34, beating the consensus estimate of $-0.36 by $0.02 per share. Revenue came in at $1.5M, missing the estimate of $5.5M.
Company Overview
Citius Pharma's stock moved following the earnings release. The stock currently trades at $0.57 with a market capitalization of $13.0M.
Citius Pharma's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Citius Pharma should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Citius Pharma Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q3 (Aug 2026) | $-0.34 | $-0.36 | +5.6% |
| Q2 (May 2026) | $-0.99 | $-0.32 | -210.9% |
| Q1 (Feb 2026) | $-0.38 | $-0.30 | -26.7% |
Related Tools: Earnings Calendar | View CTXR Stock Page
Frequently Asked Questions
When does Citius Pharma report earnings?
Check the latest earnings dates on our CTXR earnings page or the Earnings Calendar.
Did CTXR beat earnings estimates?
See the full Q3 results including EPS actual vs estimate on our CTXR earnings page.